Through relentless research and cutting-edge solutions, Fluent is reimagining diabetes management to empower children and people with diabetes to live fully and freely.
We are reimagining diabetes management to empower children and people with diabetes to live fully and freely. Through relentless research and cutting-edge solutions, we aim to achieve Zero Time Out of Range — breaking economic barriers, fighting stigmatization, and shaping a future free from diabetes complications.
Scientific rigor from the field of Formula 1 engineering applied to personalised blood glucose prediction models.
Fluent PrevYOU brings real-time personalised blood glucose predictions directly to your mobile device.
Dedicated solutions for children aged 6–12 and young users aged 12–18, with their families and caregivers.
To lead the future of pediatric diabetes care, where every child can thrive without limitations and live life on equal footing with their peers — today and tomorrow.
The personal journey that sparked the Fluent research project.
"Diabetes was one of those words I had always heard casually before meeting my wife. I learned to understand and comprehend what it means to deal with this disease through her experience, which is much more difficult to accept and face than if it were my own."
"However, I also received a great lesson: perhaps not all challenges will be won, but with intelligence and commitment, it is possible to manage diabetes well and take care of oneself."
Not long after, the idea for a research project for simpler and more effective management named Fluent was born.
Giuseppe has always been involved in research and development in a very different domain — Formula 1, Formula 2, and other automotive competitions. In this domain, he has had the privilege of helping shape the frontier of advanced technology. Beyond the breakthroughs, he has embraced a culture of innovation that sparks solutions with real competitive impact.
He believes this same spirit of innovation has inspired and keeps driving the work of all people contributing to the Fluent project.
Explore the global data: 589 million adults living with diabetes in 2024, projected to reach 852 million by 2050.
Learn how Fluent's research approach centers on individualized care for better outcomes.
Global epidemiological data from the IDF Diabetes Atlas 11th Edition (2024–2050).
Adults with diabetes globally in 2024 — representing 11.1% of all adults aged 20–79.
Projected number of adults living with diabetes by 2050 — a 45% increase in just 25 years.
While global population grows ~25%, diabetes prevalence is expected to grow nearly twice as fast.
Beyond the immediate management challenges, diabetes carries significant long-term complications when inadequately managed. These include cardiovascular disease, neuropathy, nephropathy, and retinopathy — reinforcing the urgent need for innovative management solutions like Fluent PrevYOU.
Source
International Diabetes Atlas — IDF 2025
Estimated numbers of people with diabetes in adults (20–79 years) by age group in 2024 and 2050.
Why a personalised approach is essential to achieving Zero Time Out of Range.
Fluent research project arises from the increasing prevalence of diabetes, both Type 1 and Type 2, and the need for personalised medicine approaches to enhance diabetes management and patient outcomes.
When it comes to children and adolescents, a truly personalised approach must extend beyond the individual. It must also engage and empower key figures in their lives — such as family members, teachers, and sports coaches — so they can actively contribute to achieving the goal while also easing the daily burden of diabetes management.
Every person's blood glucose response is unique. Our prediction model continuously adapts to each user's biometric patterns.
For young users, the care ecosystem includes parents, teachers, and sports coaches — all empowered with real-time guidance.
The ultimate goal: enabling every person with diabetes to maintain optimal blood glucose levels consistently.
Personalised blood glucose prediction is the key that shifts management from responding to events — to anticipating them.
It didn't take long to realise that making blood glucose predictions readily accessible to people was equally important. A prediction based on data that is hard to retrieve and/or provide to the algorithm wouldn't be very helpful for daily diabetes management. Therefore, Fluent ventured into the mobile-health space — equipping the prediction algorithm with the immediacy required for effective daily use.
The result of this journey is a mobile app called Fluent PrevYOU capable of delivering real-time personalised blood glucose predictions.
Understanding the difference between reactive and proactive diabetes management.
The mobile-health app implementing the results of Fluent research for personalised medicine and innovative diabetes care.
Fluent PrevYOU is a personalised solution for diabetes control — from real-time therapy management to blood glucose prediction.
Fluent PrevYOU empowers diabetic children and people with the world's most advanced management solution, developed to take on the "Zero Time Out of Range" challenge.
Fluent PrevYOU is currently available for Android devices only on Google Play Store.
Fluent PrevYOU's solutions cater to both Type 1 and Type 2 diabetes — ensuring comprehensive support for varying needs and conditions.
If you have been diagnosed with diabetes recently you can find some useful information here. We also invite you to check other sources such as National Diabetes Associations websites. We view education as the most powerful tool for effectively managing and overcoming diabetes challenges.
| Feature | Type 1 Diabetes | Type 2 Diabetes |
|---|---|---|
| Cause | Autoimmune: immune system attacks insulin-producing cells in the pancreas. | Insulin resistance; body doesn't use insulin properly; may later produce less insulin. |
| Onset | Usually develops in childhood or adolescence, but can occur at any age. | Typically develops in adults over 45, but increasingly seen in younger people. |
| Insulin Production | Little to no insulin produced. | Insulin produced, but not used effectively. |
| Treatment | Requires daily insulin therapy. | Managed with lifestyle changes, oral medications, sometimes insulin. |
| Symptoms | Develop quickly and are more noticeable. | Develop gradually, may go unnoticed for years. |
| Risk Factors | Genetic predisposition; not linked to lifestyle. | Family history, obesity, sedentary lifestyle, age, ethnicity. |
| Prevention | Cannot be prevented. | Often preventable through healthy lifestyle choices. |
| Prevalence | About 5–10% of diabetes cases. | About 90–95% of diabetes cases. |
Type 1 Diabetes (T1D) is a chronic autoimmune condition in which the body's immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body produces little to no insulin.
Onset: Typically develops in children, adolescents, or young adults, though it can occur at any age. The onset is usually rapid and requires immediate medical attention.
Diagnosis: Fasting blood glucose, HbA1c levels, autoantibodies (GAD, IA-2), C-peptide levels.
Treatment:
Complications (if unmanaged): Diabetic ketoacidosis (DKA); long-term: cardiovascular disease, neuropathy, nephropathy, retinopathy.
Management Goals: Maintain blood glucose within target range, prevent acute and chronic complications, improve quality of life.
A chronic condition that occurs when the body either doesn't produce enough insulin or becomes resistant to insulin, preventing glucose from entering cells efficiently. It is the most common form of diabetes, accounting for 90–95% of cases.
Causes: Insulin resistance, genetics, poor diet, physical inactivity, obesity, ethnicity (higher risk in African American, Hispanic/Latino, Native American, Asian American populations).
Management: Healthy eating, regular physical activity, weight loss, blood sugar monitoring, medications or insulin therapy as needed.
A type of diabetes that develops during pregnancy — typically between the 24th and 28th week — due to hormonal changes causing insulin resistance. Affects 5–10% of pregnancies in the U.S.
Risks for baby: High birth weight, premature birth, low blood sugar after birth, increased risk of obesity and type 2 diabetes later.
Risks for mother: Preeclampsia, cesarean delivery, future type 2 diabetes.
Management: Healthy diet and regular physical activity, monitoring blood sugar levels, insulin therapy if needed.
Breakthrough innovation: personalised blood glucose prediction and the In Range ++ feature.
At the heart of the breakthrough introduced by Fluent research lies the personalised blood glucose prediction feature implemented in Fluent PrevYOU. This cutting-edge innovation is set to revolutionize diabetes management by delivering individualized forecasts that empower users to maintain optimal glucose levels with greater precision.
Our engineers with a motorsport background developed the blood glucose prediction model using the same exact approach used in Formula 1 to predict lap times of racing cars.
A mobile version of the larger analytical model has been developed to run on a smartphone, delivering real-time predictions with immediacy required for effective daily use.
The model keeps adapting and improving its prediction capabilities with use. The more you use it, the more accurate the prediction you'll get.
This approach focuses on extending the time during which blood glucose levels remain within the target range, thereby reducing complications associated with diabetes.
We're dedicating increasing effort to developing this feature because we truly believe it has the potential to elevate your diabetes management — making it both simpler and more effective.
Together, we can transform the vision of
"Zero Time Out of Range"
into a reality.
PrevYOU Digital Therapy — seamlessly integrating continuous personalised therapy into patients' daily lives.
Current therapy prescription methods lack real-time integration with patients' lifestyles, leading to suboptimal adherence and effectiveness. People often struggle with managing their diabetes due to the absence of continuous, personalised guidance and prompts that align with their daily routines.
Research indicates that patients who do not receive continuous therapy prompts are more likely to experience poor adherence, leading to ineffective treatment outcomes. Better therapy integration into patients' daily lives can significantly improve adherence and effectiveness.
Continuous therapy integration and delivery can enable unprecedented harmonization of medical treatment and diet with patient's lifestyle. The switch to digital therapy ensures that therapy is not only prescribed but also seamlessly integrated into daily routines.
Children with diabetes face unique challenges in maintaining optimal blood glucose levels, which can impact their daily activities and long-term health. Current solutions often lack personalization and adaptability, leading to suboptimal management.
Currently under development. Provides children aged 6–12 with Type 1 diabetes, along with their parents and caregivers, an effective and personalised diabetes management solution.
Currently under development. Provides adolescents aged 12–18 with Type 1 diabetes, along with their parents and caregivers, a tailored effective management solution.
In the case of youngsters, the extended Caregiver Team — represented by family members, teachers, and sport coaches — can greatly benefit from the real-time prompts provided by the digital therapy implementation into Fluent PrevYOU to get guidance on how to help young people better manage their condition.
The continuous therapy integration and delivery features of Fluent PrevYOU offers doctors and healthcare providers the possibility to enable unprecedented harmonization of medical treatment and diet with patient's lifestyle.
Our committed areas of R&D for the next phase of Fluent PrevYOU development.
Although Fluent research has already delivered breakthroughs which are now making possible to reach the "Zero Time Out of Range" condition, we are fully committed to further improving the effectiveness of our solution for diabetes management.
Below is a summary of the research and development areas we will be focusing on in the near future.
Further development and validation of the mathematical model for personalised blood glucose prediction — enabled by the increasing volume of user data from real-world life conditions.
Further development of Fluent PrevYOU "In Range ++" feature which suggests patterns of actions offering longer time in range potential.
Improvements to Fluent PrevYOU continuous therapy integration and delivery features to enhance therapy adherence and effectiveness.
Improvements to the workflow currently available to doctors and dieticians for digital therapy implementation and upload into Fluent PrevYOU.
Ongoing and future developments include a version of the app specifically designed for children aged 6–12 and young users aged 12–17, incorporating gamification (Zoor & Zoory mascots) and age-appropriate UX.
Join our early access programs to be among the first to experience and help shape the next generation of Fluent PrevYOU — tailored for children, young users, and healthcare providers.
Fluent researchers are currently working on a tailored solution of PrevYOU for children. Our gamified version relies on Zoor and Zoory (acronyms of Zero Out of Range) — helping communicate with children in their language and giving voice to continuous therapy prompts.
Fluent researchers are currently working on a tailored solution of PrevYOU for young users. Unlike the children's version, we are evaluating several design options for this age group.
By joining the early access program, you'll help us shape this version to better suit you and others in this group.
The digital therapy features of Fluent PrevYOU offer doctors and healthcare providers the possibility to enable unprecedented harmonization of medical treatment and diet with patient's lifestyle.
If you are a doctor or caregiver interested in the possibilities offered by Fluent PrevYOU such as digital therapy implementation, please join our early access program.
Academic partnership and research collaboration.
The University of Verona represents one of Fluent's key academic partnerships, contributing to the research and validation of the personalised blood glucose prediction model. This collaboration bridges academic rigor with real-world application.
Joint research activities supporting the development and validation of Fluent's core blood glucose prediction technology.
Academic medical expertise informing the clinical validity and applicability of Fluent PrevYOU's personalised medicine approach.
Academic partnership and research collaboration.
Content for the Padova academic partnership is currently being prepared. Please check back soon for updates on this collaboration.
PrevYOU support, educational program enquiries, and investor relations.
Technical support and questions about the Fluent PrevYOU mobile app.
[email protected]Apply to join early access programs for children, young users, or healthcare providers.
[email protected]Enquiries about Fluent's educational programs in collaboration with IDF and ISPAD.
[email protected]Information about strategic research areas and investment opportunities.
[email protected]Partnerships with IDF and ISPAD to support diabetes education globally.
Fluent's educational programs in collaboration with IDF (International Diabetes Federation) and ISPAD (International Society for Pediatric and Adolescent Diabetes) are being finalized. Contact us for early enquiries.
A transformative approach to medical research — and a compelling platform for the future of precision medicine.
Fluent PrevYOU mobile health platform provides access to longitudinal patient data collected under real-world conditions, encompassing diverse age groups, genders, and biometric profiles — offering a uniquely rich dataset for translational and clinical research applications.
Ongoing exploration and validation of AI-driven predictive models using real-world data to further advance precision medicine.
Research into digital twin technology for personalised diabetes simulation and treatment optimization.
Exploring integration with next-generation wearable biosensor technology for richer real-time data.
Building systems for seamless real-time data integration across devices, clinicians, and care teams.
If interested in learning more about the strategic research areas for diabetes and other diseases that are currently shaping our innovation pipeline, please contact us.
The Fluent PrevYOU mobile-health app is completely free — because we believe everyone should have access to the most advanced tools for managing diabetes. We've removed financial barriers so anyone can join the journey toward "Zero Time Out of Range."
If Fluent PrevYOU is helping you or someone you care about, consider supporting our mission. Your donation helps keep the app free, expand access to those who need it most, and continue developing life-changing features.
Every contribution — big or small — makes a real difference.